Recorded Presentation from the NCCN Pharmacy Updates: Understanding the Molecular Heterogeneity of Diffuse Large B-Cell Lymphomas and the Place of Targeted Therapies in Treatment
New promising combinations of chemoimmunotherapy with antibody drug conjugates, and small molecule inhibitors may offer an alternative approach for patients with relapsed or refractory disease. Many of these new therapies are oral and will be managed by a multidisciplinary team.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: Diagnosis and Management of Marginal Zone Lymphomas
Marginal zone lymphomas (MZLs) represent a clinical challenge due to their heterogeneity, and the relative rarity of individual subtypes has largely precluded the use of standard treatment approach across all subtypes. Educating clinicians about the biology of MZLs, novel therapeutic approaches, and special considerations will help them to develop an individualized treatment plan to optimize clinical outcomes.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Updates in the Management of Early-Stage Diffuse Large B-Cell Lymphoma
Clinicians are challenged to remain up-to-date with the recent advances in the management of early stage DLBCL, and education will help them to make informed decisions in their routine clinical practice.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Diffuse Large B-Cell Lymphoma: Optimizing Therapy for Relapsed/Refractory Disease
The advent of novel targeted therapies represents a major paradigm shift for management of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Outcomes of relapsed/refractory DLBCL differ based on the response to initial therapy, timing of relapse, and opportunity to undergo transplant. A multidisciplinary approach is required for appropriate patient selection and the management of acute toxicities to prevent fatal outcomes.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Updates in the Treatment of Lymphoma
This presentation will help guide nurses in the use of novel agents, the timing of those agents, and the treatment when a patient has progressed after first-line therapy. New agents will be discussed, including administration information, side effects, and helpful patient education information for nursing.
Category
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Toxicities of CAR T-Cell Therapy: Beyond CRS and Neurotoxicity
The information presented in this talk will address the long-term effects of CAR T-cell therapy, including HLH/MAS, B-cell aplasia, and prolonged cytopenias. Nurses will learn how to recognize signs/symptoms of these effects and how to manage them in order to educate patients and provide ideal care to patients undergoing CAR T-cell therapy.
Category
  • Acute Lymphoblastic Leukemia
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Updates to the Management of Patients with Relapsed/Refractory Indolent B-Cell Lymphomas
Oncologists and hematologists need to maintain high awareness of the recently approved targeted therapies and the precise indications for their use so that these can be incorporated in routine clinical practice in the appropriate patient population.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation